@eyeswideopen for clarity, I believe that your list is by revenue?
Novartis has a market cap of around $200 billion on revenue of around $48 billion. Top J&J as you show market cap $400 billion double Novartis, revenue only about $9 billion more.
What I find interesting (if I have the correct figures) is that Entresto accounted for nearly $2.5 Billion of those Norvartis sales. The first choice heart treatment option, 45% growth whereas overall company managed net sales growth of 3% (I believe)
So where can they find new therapies to drive a similar double digit growth as Entresto and close that gap with J&J?
Any suggestions, I am sure you can reach them in Switzerland.
regards
Yelrom
Mesoblast Partnership Announcements, page-84
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |